Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EBITDA (2019 - 2025)

Volitionrx (VNRX) has disclosed EBITDA for 9 consecutive years, with -$5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 10.37% year-over-year to -$5.4 million, compared with a TTM value of -$23.6 million through Sep 2025, up 22.05%, and an annual FY2024 reading of -$27.1 million, up 23.96% over the prior year.
  • EBITDA was -$5.4 million for Q3 2025 at Volitionrx, up from -$6.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.4 million in Q3 2025 and bottomed at -$9.5 million in Q2 2023.
  • Average EBITDA over 5 years is -$7.3 million, with a median of -$7.5 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 67.89% in 2021, then soared 36.2% in 2024.
  • Year by year, EBITDA stood at -$8.8 million in 2021, then grew by 15.49% to -$7.4 million in 2022, then fell by 18.46% to -$8.8 million in 2023, then skyrocketed by 36.2% to -$5.6 million in 2024, then rose by 4.0% to -$5.4 million in 2025.
  • Business Quant data shows EBITDA for VNRX at -$5.4 million in Q3 2025, -$6.9 million in Q2 2025, and -$5.7 million in Q1 2025.